Leading Edge Genomic Services & Solutions

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com

PacBio Announces New Agreement with Novogene to Purchase Ten Sequel Systems – Increases Novogene’s Capacity to Run 20 Sequel Systems at a Time

MENLO PARK, Calif., and SAN DIEGO, Calif., August 2, 2017 — Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene Corporation today announced a new agreement by Novogene to purchase 10 Sequel® Systems, giving the DNA sequencing service provider the capacity to run up to 20 Sequel Systems at a time.

Novogene, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, is the largest user of PacBio’s Sequel Systems in the world. The service provider has ramped its use of the system dramatically since earlier in the year when it acquired acesss to the first 10 Sequel Systems through the Nanjing Yangzi State-Owned Investment Group in China.

The Sequel System, based on PacBio’s unique Single Molecule, Real-Time (SMRT®) technology, provides an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology allows scientists to go beyond fragmented draft genomes and generate the most comprehensive de novo assemblies.

“The overwhelming demand for SMRT Sequencing in the few months since we began running the Sequel Systems has required us to double our capacity in a short amount of time,” said Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “Some of the large projects we have planned include building a database of structural variants in 1,000 Chinese individuals as part of the Chinese precision medicine initiative. In addition, we have partnered with the Global Ant Genomics Alliance to sequence 300 different species of ants to provide a comprehensive look at genomic diversity in ant genera.”

Michael Hunkapiller, Ph.D., Chairman and CEO of PacBio added: “Novogene has very quickly become the largest user of our Sequel platform, and is now operating the largest SMRT Sequencing service center in the world. We are delighted that they have successfully ramped up their utilization of the systems so quickly, and that high demand for SMRT Sequencing services in China has led them to already increase their capacity.”

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product orders, future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the company’s agreement with Novogene, the suitability of the company’s products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

For PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

Novogene Adds 25 Illumina NovaSeq Sequencers

April 3, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced the order of 25 Illumina NovaSeq 6000 sequencers. Five of the sequencers will be located in the U.S. In addition, Novogene will operate the 20 units purchased by Nanjing Yangzi State Owned Investment Group in China. With the addition of these new NovaSeq sequencers to its existing array of 30 Illumina HiSeq X and 10 PacBio Sequel systems, Novogene now offers the largest and most advanced sequencing capacity in the world with annual throughput of 280,000 human whole genomes.

The addition of the NovaSeq sequencers not only expands Novogene’s sequencing capacity, but also greatly reduces its sequencing cycle times. With NovaSeq, Novogene will be able to sequence up to 48 human whole genomes, producing 6Tb of data, per single run as short as 40 hours. To match NovaSeq’s high capacity and efficiency, Novogene also upgraded its data storage and computing power to 878T flops, total memory of 368TB, and total storage of 29PB.

Introduced by Illumina in January 2017, NovaSeq is a highly powerful sequencer designed to be scalable and flexible for virtually any genome, method, and scale of project. In human disease research, Novogene’s addition of the NovaSeq sequencing platform will enable the study of rare genetic variations with larger sample size, greater depth and faster speed, and accelerate the progress of global precision medical research.

“We were among the first to receive Illumina’s HiSeq X sequencers when they were first introduced, so we are pleased to now be among the first to adopt the new NovaSeq sequencing system,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “We look forward to bringing the benefits of this powerful new sequencing system to our customers through affordable, flexible and scalable solutions for their diverse research needs.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com


Two NovaSeq instruments installed on-site.

Novogene NGS Medical Lab Receives CAP Accreditation

April 4, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced that its next-generation sequencing (NGS) medical lab in Tianjin, China has received accreditation from the College of American Pathologists (CAP). With CAP accreditation, Novogene now will be able to provide its high-quality, well-established clinical sequencing services to customers throughout the world.

The process of CAP accreditation involves a rigorous series of inspections and certifications on lab quality management systems, experimental processes, data analysis and clinical interpretation. CAP accreditation, received on March 30th, 2017, attests to Novogene Tianjin medical lab’s global comparability and competitiveness for NGS sample quality control, personnel qualification, facilities, and quality assurance.

Novogene established its clinical service division in January 2014, and has continuously developed its clinical services in China, including tumor gene detection and genetic testing services. Novogene also established a Precision Medicine Center of Excellence with Thermo Fisher Scientific in December 2016 and is one of the first China National Genetic Testing Technology Demonstration Centers.

“Our strategy is to incorporate scientific research, clinical diagnostics, and preventive medicine synergistically to drive life science research and improve human healthcare,” stated Dr. Ruiqiang Li, CEO of Novogene. “CAP accreditation represents an important milestone for our Tianjin medical center, which can now provide superior clinical services to our more than 450 hospital customers and pharmaceutical partners globally for projects of any scale, in ways that we could not before.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journals such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene receives the 2017 Innovation and Excellence Award from Corporate LiveWire

We are proud to announce that Novogene and our Founder and CEO Ruiqiang Li have been honored with a 2017 Innovation and Excellence Award from Corporate LiveWire, a UK-based provider of business information to the corporate finance sector. The Innovation & Excellence Awards give recognition to businesses that are transforming their respective industries and the standard-bearers of excellence by continually setting industry trends as well as showing significant advances in terms of innovation and improvement.

The Innovation and Excellence Awards are sponsored by The International Business Innovation Association (InBIA), a global non-profit member network that serves a diverse group of 2,200+ entrepreneurship centers. InBIA helps guide, mentor and develop sustainable entrepreneurial programs in every industry and demographic around the globe. In selecting Novogene and Dr. Li, the judging panel at Corporate LiveWire cited the way Novogene has embraced advanced technology, including its use of Illumina HiSeq and PacBio Sequel systems, as integral to the company’s success. The panel also cited Novogene’s dedication to scientific excellence, customer service, data quality, highly trained team and extensive portfolio of patents and publications as key differentiators for the company.

Novogene Agrees to Buy Ten PacBio Sequel Systems for DNA Sequencing Services

MENLO PARK, Calif., and BEIJING, China — January 16, 2017 — Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene Corporation, a leading provider of genomic and bioinformatic services, today announced that Novogene has agreed to purchase 10 Sequel™ Systems for whole genome sequencing, Iso-Seq™ annotation and targeted sequencing services.

PacBio’s sequencing systems are based on its unique Single Molecule, Real-Time (SMRT®) technology, and provide an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology allows scientists to go beyond fragmented draft genomes and generate the most comprehensive de novo assemblies.

Ruiqiang Li, Ph.D., Founder and CEO of Novogene commented: “Novogene is a global leader in de novo sequencing and assembly today, and our purchase of ten PacBio Sequel Systems will advance our ability to produce even higher quality and more complete de novo genome assemblies. The addition of these systems, and the ability to sequence large genomic libraries that yield mean read lengths of 10-18kb, also will enable us to meet the growing demand for SMRT Sequencing and to deliver more cost-effective de novo sequencing and assembly solutions for our customers. With this purchase, we expect to have the world’s largest SMRT Sequencing facility.”
Michael J. Hunkapiller, Ph.D., Chairman and CEO of PacBio added: “We are delighted to receive such a significant endorsement of our technology from a world-class sequencing facility. This follows a recent trend by leading institutions around the world investing in multiple SMRT Sequencing systems— oftentimes to complement their existing PacBio RS II instruments. Moreover, it underscores that adoption of SMRT Sequencing to answer some of the most challenging questions in genomics and medicine is increasing steadily.”

Novogene will announce its purchase of the PacBio Sequel systems today at its workshop at the Plant and Animal Genome XXV Conference in San Diego, where Novogene will be discussing how SMRT technology and other cutting edge sequencing technologies help improve the results of de novo assemblies for a variety of species. Novogene’s workshop – Latest NGS Applications in Agricultural Research – is being conducted Monday, January 16, 2017 from 6:10 PM to 8:20 PM in the Pacific Salon 1 at the Town and Country Hotel.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com

About Novogene Corporation

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 43 NGS related patents, and over 200 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product orders, future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the company’s agreement with Novogene, the suitability of the company’s products for particular markets or applications and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Media Contacts:

Contacts for PacBio:

Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

For Novogene:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

Novogene Establishes First U.S. Genomic Sequencing Center Located at UC Davis; Acquires Second Illumina Hi-Seq X Ten System

April 14, 2016, San Diego – Novogene, a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, announced today that it has established its first genomics sequencing center in the United States, located on the Sacramento campus of the University of California, Davis. The company also announced that it has purchased its second Illumina Hi-Seq X Ten system — the first system to enable whole human genome sequencing for less than $1,000 — and that it is installing five of these sequencers in the newly established facility at UC Davis.

The purchase of a second Hi-Seq X Ten system adds further to Novogene’s NGS sequencing capacity, among the largest in the world at 36,000 human genomes per year. Novogene was the first company in China to acquire Illumina’s Hi-Seq X Ten system when introduced in early 2014, and has extensive experience using the system to provide whole genome sequencing service.

Novogene’s genome sequencing center at UC Davis, scheduled to open in early May, will provide to U.S. and global customers high-quality whole genome sequencing and analysis of human, plant and animal samples for biomedical and agricultural research. Novogene’s goal is to establish a CLIA-certified laboratory in the UC Davis facility to enable human genome sequencing for clinical applications as well, including the diagnosis, prevention and treatment of disease. In addition to the ultra-high-throughput Illumina Hi-Seq X instruments, the facility will incorporate other state-of-the-art NGS technologies coupled with Novogene’s cutting-edge bioinformatics and analytical capabilities. In addition to serving the needs of researchers globally, Novogene anticipates that the facility will also benefit UC Davis scientists focused on cancer, regenerative and precision medicine, animal and agricultural research, as well as its broader academic community.

“We are proud to announce the establishment of our first genomic center in the U.S. as well as the acquisition of our second Illumina Hi-Seq X Ten system,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “We look forward to providing U.S.-based NGS services and bioinformatics analyses in support of diverse global genomics research needs. As one of the first and largest users of Illumina’s HiSeq X Ten systems, we are uniquely positioned to rapidly provide customers with the highest quality whole genome sequencing data.”

About Novogene

Novogene Bioinformatics Technology Company, Ltd., headquartered in Beijing with branches in the U.S. and United Kingdom, is a leading genomics solution provider with cutting edge bioinformatics expertise and one of the largest sequencing capacities in the world. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed nearly 10,000 projects and sequenced 140,000-plus samples for more than 6,000 global customers, with research findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X Ten system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA.

Please see https://en.novogene.com for more information.

Media Contact:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Full Genomes™ Corporation Collaborates with Novogene to Offer Low-cost Whole Genome Ancestry Test

Comprehensive GenomeGuide now available at $895

January 28, 2015, Rockville, MD and San Diego and Beijing – Full Genomes™ Corporation, the first company to offer a high-resolution and comprehensive Y chromosome test in January 2013, announced today that it is collaborating with Novogene, a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, to offer GenomeGuide , one of the first whole genome tests for ancestry purposes for under $1,000.

GenomeGuide, now available to consumers at $895, includes raw data (BAM file), variant summary reports from SnpEff and VEP that are compatible with third party tools, such as Promethease, autosomal and X-chromosomal variant identification (Variant Call Format) files , and mitochondrial and Y chromosome reports (for males). As with other Full Genomes products, GenomeGuide is intended for ancestry/research-use only, and should not be relied upon for medical or diagnostic purposes.

Novogene, the only Illumina Genome Network partner in China, will deliver high-quality WGS data using the Illumina Hi-Seq X Ten system capable of sequencing up to 18,000 human genomes per year at the lowest cost per genome, and will apply its advanced bioinformatics capabilities and expertise to provide variant analysis.

“The advent of new technology has enabled Full Genomes to offer GenomeGuide, a new whole genome ancestry test which will be the most comprehensive ancestry test on the market today,” stated Justin Loe, CEO of Full Genomes. “Full Genomes is committed to providing responsible and detailed genetic reports to the customer,” he added, “and we are incorporating the latest technology to enable the consumer to receive comprehensive information on their ancestry. With their advanced Illumina technology, outstanding informatics/analysis, and highly responsive and effective support, we are confident that Novogene will deliver the high-quality WGS results our customers expect.”

“We look forward to collaborating with Full Genomes and to helping enable the delivery of this highly cost competitive ancestry research to consumers,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “As one of the first companies in the world to purchase Illumina’s HiSeq X Ten in early 2014, we have extensive experience with the system and are uniquely positioned to provide Full Genomes and its customers with the highest quality WGS data.”

About Full Genomes Corporation

Full Genomes incorporated in 2012 for the purpose of making full genomic sequencing for genealogical use available to the general public at a leading price point. Full Genomes introduced Y Elite, a comprehensive (next generation sequencing) of the Y chromosome in 2013 to the genetic genealogy market. Since then, a variety of customers in the U.S. and overseas, as well as a number of institutions have used FGC’s Y chromosome product. Full Genomes’ proprietary DNA analysis capabilities for the Y chromosome have been recognized and have been used for a variety of research projects. Full Genomes has partnered with various vendors and organizations for sequencing and chip development with the goal of advancing new products and DNA services addressing additional markets.

About Novogene

Novogene Bioinformatics Technology Company, Ltd., headquartered in Beijing with branches in the US and UK, is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed numerous major service projects with findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X 10 system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA. To learn more, visit https://en.novogene.com.

For more information, contact:

Justin Loe
Chief Executive Officer
Full Genomes Corporation
424-333-8537
justin.loe@fullgenomes.com

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications

December 14, 2015, Beijing & San Diego — Novogene, a leading global provider of genomic services and solutions, and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.

In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine. The collaboration between Novogene and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.

The collaboration will bring together technology from Illumina sequencers with Novogene’s advanced clinical application development capabilities. As part of the agreement, Novogene will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.

“As a global provider of high-quality genomic services and leading edge bioinformatics solutions, Novogene is pleased to partner with Illumina to advance the application of NGS technology in precision medicine,” said Dr. Ruiqiang Li, Novogene Founder and Chief Executive Officer. “As the first company in China to purchase Illumina’s HiSeq X Ten System and the largest provider of Illumina-based sequencing capacity in China, Novogene welcomes this opportunity to improve the quality of care enjoyed by the Chinese people.”

“Illumina is very excited to collaborate with Novogene to increase access to genetic sequencing solutions in the fields of reproductive health and oncology testing in China,” said Tim Orpin, General Manager of the Asia Pacific Region for Illumina. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.”

About Novogene

Novogene, headquartered in Beijing with branches in Hong Kong, the U.S. and U.K., is a leading provider of genomic services and solutions with leading edge bioinformatics expertise. Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. To learn more, visit www.novogene.com.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statement for Illumina

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

For more information, contact:

Novogene
Joyce Peng, Ph.D.
626-222-5584
joyce.peng@novogene.com

or

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com

or

Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Novogene and International Center for Tropical Agriculture to Construct Pan-genome of Cassava

– Novel research approach will unravel the evolutionary history and genetic diversity within the cassava genus and advance cultivation of the world’s third most important food source –

December 3, 2015, San Diego, Beijing, and Cali, Colombia – Novogene, a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, and the International Center for Tropical Agriculture (CIAT), a global agricultural research and development organization and custodian of the world’s largest cassava gene bank, are partnering to construct a pan-genome of cassava (Manihot esculenta) and one of its closest wild relatives (M. e. peruviana). This novel approach to global cassava genome research is designed to unravel the plant’s complex evolutionary history and genetic diversity with the goal of increasing the production and nutritional value of a primary food source in Africa, Latin America and the Caribbean.

Under the pan-genome sequencing project, Novogene will sequence and assemble cassava genomes provided by CIAT from six different eco-geographic zones, and conduct comparative genomic analysis among these genomes in relation to M. e. peruviana. The pan-genome will include the cassava’s core-genome, containing genes present in all of cassava’s ecogeographic zones of domestication (Mesoamerican-Caribbean, Savanna, Andean, South America Lowland Forest, Amazon, Humid Atlantic Forest and Dry Atlantic Forest); the dispensable-genome, containing genes present in two or more ecogeographic zones; and unique genes specific to single ecogeographic adaptation regions, including those from M. e. peruviana.

Since the initial publication of the cassava reference genome, attempts have been made to characterize cassava through genome resequencing to unlock important sources of genetic diversity to improve varieties that will meet future productivity, nutrition and environmental challenges. However, resequencing has often failed to capture many types of structural variation related to agronomic traits, including copy number variation and presence-absence variation, especially for the most genetically diverse lines and the crop’s wild relatives because the reference genome was developed using a single inbred genome. Next-generation sequencing and state-of-the-art assembly algorithms make the construction of pan-genome maps feasible, and the construction of genome maps for individual or multiple strains provides unprecedented opportunities to investigate detailed genetic diversity at the population level.

“This research represents a significant step forward in demonstrating the value of pan-genome de novo assemblies in building and characterizing the genes that pave the path to the domestication of cassava out of the Manihot tribe,” stated Dr. Luis Augusto Becerra Lopez-Lavalle, Cassava Molecular Geneticist at CIAT, “and provides candidate genes for introgression into today’s cassava for crop improvement.” Added Dr Joe Tohme, AgBiodiversity Director of CIAT, “We welcomed the opportunity to partner with Novogene given their high-quality sequencing capabilities, cutting edge bioinformatics technology and expertise, and pan-genomic research experience.”

“Novogene is a pioneer and world leader in the assembly and analysis of pan-genome maps,” stated Dr. Ruiqiang Li, Founder and Chief Executive Officer of Novogene. “Our pan-genomic research studies, including the wild relative of cultivated soybean, have been published in leading scientific journals. We look forward to applying this experience and expertise to the creation of the cassava pan-genome with the objective of enhancing global cultivation of this important food source.”

About Cassava

Cassava is the world’s third most important source of dietary energy after maize and rice. Half-a-billion people in Africa as well as Latin America and the Caribbean depend on this root crop for food, and millions of Asian farmers grow it for industrial markets. Cassava can withstand harsh conditions, making it a key crop for protecting smallholder farming against climate change. Esteemed by smallholder farmers for its tolerance to drought and infertile soils, the crop is inherently eco-efficient, offering a reliable source of food as well as income from markets for a wide variety of food, feed, pharmaceutical and industrial products.

About CIAT

The International Center for Tropical Agriculture (www.ciat.cgiar.org) is a not-for-profit research and development organization dedicated to reducing poverty and hunger while protecting natural resources in developing countries. It is based in Cali, Colombia.

CIAT is part of the CGIAR Consortium, a global partnership that unites organizations engaged in research for a food-secure future. CGIAR research is dedicated to reducing rural poverty, increasing food security, improving human health and nutrition, and ensuring more sustainable management of natural resources. Donors include individual countries, major foundations, and international entities. This project was made possible with the financial support of the Federal Ministry for Economic Cooperation and Development, Germany, with support from the German Society for International Cooperation (GIZ) GmbH.

About Novogene

Novogene Bioinformatics Technology Company, Ltd. (www.novogene.com), headquartered in Beijing with branches in the US and UK, is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed numerous major service projects with findings published by top-ranked journals such as Science and Nature. Novogene is the first company in China to purchase Illumina’s HiSeq X 10 system and is the only Illumina Genome Network partner in China. Novogene Corporation is Novogene’s U.S. subsidiary, based in San Diego, CA.

For more information, contact:

Luis Augusto Becerra Lopez-Lavalle
Principal Research Scientist and Cassava Molecular Geneticist
Agrobiodiversity Research Area – Cassava Program
International Center for Tropical Agriculture (CIAT)
l.a.becerra@cgiar.org

Joe Tohme
Research Director
Agrobiodiversity Research Area
International Center for Tropical Agriculture (CIAT)
j.tohme2@cgiar.org

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com